C. Purpose of this Guidance, Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA

  • To outline the practical arrangements for notification.
  • To provide advice on what should and what should not be classified as a “serious breach” and what must be reported.
  • To outline possible actions that may be taken by the MHRA in response to notifications of serious breaches.

Back to the index of the Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA, Medicines & Healthcare products Regulatory Agency

Clinical Research News

Efter slagtilfælde og hjerneblødning: Nyt studie tester, hvornår blodfortyndende medicin er nødvendig
Første AI-designede vaccine fuldfører forsøg på mennesker
Blod i urinen og mistanke om tumor: Ny urintest sammenlignes med cystoskopi og biopsi
Når ultralyd viser en anomali, men genetikken er tavs: WGS testes i Kina
Kronisk pancreatitis og kræftrisiko: Forskere leder efter spor i immunsystemet
Protecting the Heart Before Going Home: Hospitals Test Giving Flu Shots Right Before Discharge
High Cholesterol: New Non-Statin Drug to Be Compared Directly With Bempedoic Acid

Kommende kliniske forsøg

Clinical Research Jobs

More jobs

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

Abonner